Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vaidyane Ayurved LaboratoriesNSE:MADHAVBAUG 77 PB Ratio is 2.62 as of Jul. 30, 2026, which is 37% below its 10-year median of 4.19. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 77/100 and a GF Value™ of ₹228.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Vaidyane Ayurved Laboratories ranks worse than 64.6% on this metric.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's PB Ratio or its related term are showing as below:
NSE:MADHAVBAUG'
s PB Ratio Range Over the Past 10 Years
Min: 1.77 Med: 4.19 Max: 20.84
Current: 2.62
During the past 8 years, Vaidyane Ayurved Laboratories's highest PB Ratio was 20.84. The lowest was 1.77. And the median was 4.19.
NSE:MADHAVBAUG's PB Ratio is ranked worse than 64.6% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs NSE:MADHAVBAUG: 2.62
During the past 12 months, Vaidyane Ayurved Laboratories's average Book Value Per Share Growth Rate was 31.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 43.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Vaidyane Ayurved Laboratories was 78.60% per year. The lowest was 20.30% per year. And the median was 59.90% per year.
Back to Basics: PB Ratio
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vaidyane Ayurved Laboratories PB Ratio Related Terms
Vaidyane Ayurved Laboratories PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's PB Ratio falls into.
Vaidyane Ayurved Laboratories PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a PB Ratio of 2.62 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 37% below median its historical median of 4.19. Over the past decade, Vaidyane Ayurved Laboratories' PB Ratio has ranged from 1.77 to 20.84. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #595 out of 921 companies in the Drug Manufacturers industry, placing it in the top 64.6%.
Is Vaidyane Ayurved Laboratories' PB Ratio too high?
Vaidyane Ayurved Laboratories' current PB Ratio of 2.62 is 37% below median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 20.84. The Drug Manufacturers industry median PB Ratio is 1.86. Vaidyane Ayurved Laboratories' value of 2.62 is 40.9% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #595 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #595 out of 921 companies for PB Ratio. This places Vaidyane Ayurved Laboratories in the lower half of its industry. The industry median PB Ratio is 1.86. Vaidyane Ayurved Laboratories' value of 2.62 is 40.9% above this benchmark. Historically, Vaidyane Ayurved Laboratories' own PB Ratio has ranged from 1.77 to 20.84 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 1.86, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current PB Ratio of 2.62 is 40.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current PB Ratio is 2.62, which is 37% below median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.18, compared to a current price of ₹191.90 — trading 15.9% below its estimated fair value. The current PB Ratio is 2.62, which is 37% below median its 10-year median of 4.19 and 40.9% above the Drug Manufacturers industry median of 1.86. Vaidyane Ayurved Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current PB Ratio is 2.62 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹191.90 is trading 15.9% below its estimated GF Value™ of ₹228.18.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
PB Ratio: 2.62 (37% below median its 10-year median of 4.19)
GF Value™: ₹228.18 vs. price of ₹191.90 (15.9% below fair value)
Industry Position: 40.9% above the Drug Manufacturers median (#595 of 921)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
77GF Score
Get the complete analysis for NSE:MADHAVBAUG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
